KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $1.55.

  • Rigel Pharmaceuticals' EPS (Basic) rose 11830.99% to $1.55 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.33, marking a year-over-year increase of 265217.39%. This contributed to the annual value of $0.99 for FY2024, which is 16899.8% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its EPS (Basic) stood at $1.55 for Q3 2025, which was up 11830.99% from $3.33 recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year EPS (Basic) high stood at $3.33 for Q2 2025, and its period low was -$0.47 during Q1 2024.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.08 (2021), whereas its average is $0.28.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' EPS (Basic) plummeted by 48750.0% in 2024, and later soared by 565000.0% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' EPS (Basic) stood at -$0.14 in 2021, then skyrocketed by 158.7% to $0.08 in 2022, then plummeted by 39.15% to $0.05 in 2023, then skyrocketed by 1529.44% to $0.81 in 2024, then surged by 90.25% to $1.55 in 2025.
  • Its EPS (Basic) stands at $1.55 for Q3 2025, versus $3.33 for Q2 2025 and $0.64 for Q1 2025.